The Technical Analyst
Takeda Pharmaceutical [TAK]
Exchange: NYSE Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
Takeda Pharmaceutical Price, Forecast, Insider, Ratings, Fundamentals & Signals
-1.66% $13.06
America/New_York / 8 mai 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 40 981 mill |
| EPS: | 0.370 |
| P/E: | 35.30 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 3 137.87 mill |
| Avg Daily Volume: | 1.641 mill |
| RATING 2024-05-08 |
|---|
| A- |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Buy | |
| DE: | Strong Buy | |
| P/E: | Neutral | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 2.29x |
| Company: PE 35.30 | sector: PE 15.43 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 1.29x |
| Company: PE 35.30 | industry: PE 27.41 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 12.89 - 13.23 ( +/- 1.33%) |
| ATR Model: 14 days |
Forecast:
16:00 - $13.06
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $13.06
Forecast 2: 16:00 - $13.06
Forecast 3: 16:00 - $13.06
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $13.06 (-1.66% ) |
| Volume | 1.563 mill |
| Avg. Vol. | 1.641 mill |
| % of Avg. Vol | 95.21 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For TAK
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
TAK
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Latest Press Releases
2024-04-26 08:30:00 - Press Release
Takeda Receives Positive Chmp Opinion For Fruquintinib In Previously Treated Metastatic Colorectal Cancer
Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today announced that the european medicines agency's (ema) committee for medicinal products for human use (chmp) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (vegfr) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mcrc). the european commission (ec) will consider the chmp positive opinion when.
2024-04-23 07:00:00 - Press Release
Neurocrine Biosciences Reports Positive Phase 2 Data For Nbi-1065845 In Adults With Major Depressive Disorder
Savitri™ study met primary endpoint with statistically significant reduction in montgomery Åsberg depression rating scale ( madrs) total score at day 28 met key secondary endpoints, including statistically significant reduction in madrs score at day 56 nbi-1065845 was generally well-tolerated san diego , april 23, 2024 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix), today announced positive topline data for its phase 2 savitri™ study. this randomized, double-blind, placebo-controlled dose-finding study assessed the efficacy and safety of nbi-1065845 in adult subjects with major depressive disorder (mdd).
2024-04-22 04:10:00 - Press Release
Takeda, Astellas And Sumitomo Mitsui Banking Announce Master Agreement To Establish Joint Venture Company For Incubation Of Early Drug Discovery Programs
Tokyo , april 22, 2024 /prnewswire/ -- takeda pharmaceutical company limited (tse: 4502/nyse: tak, president and ceo; christophe weber, "takeda"), astellas pharma inc. (tse: 4503, president and ceo: naoki okamura, "astellas"), and sumitomo mitsui banking corporation (president & ceo: akihiro fukutome, "smbc") today announced that the three companies signed a master agreement on april 22, 2024, to establish a joint venture company. the new company will be dedicated to the incubation*1 of early drug discovery programs, primarily originating from japan and toward the creation of innovative therapeutics.
2024-04-18 19:00:00 - Press Release
U.s. Fda Approves Subcutaneous Administration Of Takeda's Entyvio® (vedolizumab) For Maintenance Therapy In Moderately To Severely Active Crohn's Disease
Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today announced that the u.s. food and drug administration (fda) has approved entyvio® (vedolizumab) subcutaneous (sc) administration for maintenance therapy in adults with moderately to severely active crohn's disease (cd) after induction therapy with intravenous (iv) entyvio.1 the subcutaneous administration of entyvio was also approved by fda in september 2023 for the maintenance treatment of adults with moderately.
2024-04-08 08:00:00 - Press Release
Takeda Announces New U.s. Corporate Social Responsibility Program Partners To Build Equity Through Stem Education And Access To Nutritional Food
Cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today announced the selection of eight new u.s. non-profit organizations as grant recipients, as part of its $14.6 million commitment to its fy2023 u.s. corporate social responsibility (csr) program. to create greater impact and foster equity in under-resourced communities, the company is focusing its philanthropic efforts on the two areas of food is health and building stem (science, technology, engineering and math) foundations and.
Latest News
2024-05-09 02:16:02 - Reuters
Japan's Takeda Pharma says full-year profit slumps 56%
Japan's Takeda Pharmaceutical said full-year earnings slumped by 56% as the company focused on rebuilding its drug pipeline to make up for the loss of patent protection for major sellers.
2024-04-29 10:36:04 - Zacks Investment Research
Down -6.19% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround
Takeda Pharmaceutical Co. (TAK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
2024-04-26 10:36:10 - Zacks Investment Research
Down -5.9% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround
Takeda Pharmaceutical Co. (TAK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
2024-04-25 13:00:28 - Zacks Investment Research
All You Need to Know About Takeda Pharmaceutical Co. (TAK) Rating Upgrade to Strong Buy
Takeda Pharmaceutical Co. (TAK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
2024-04-25 12:45:34 - Zacks Investment Research
TAK or CTLT: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical - Drugs stocks have likely encountered both Takeda Pharmaceutical Co. (TAK) and Catalent (CTLT). But which of these two stocks presents investors with the better value opportunity right now?
2024-04-25 10:46:30 - Zacks Investment Research
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
2024-04-25 07:56:04 - Zacks Investment Research
New Strong Buy Stocks for April 25th
TAK, TXO, PEPG, ERO and RMNI have been added to the Zacks Rank #1 (Strong Buy) List on April 25, 2024.
2024-04-25 07:16:10 - Zacks Investment Research
Best Value Stocks to Buy for April 25th
RMNI, TAK and ASBFY made it to the Zacks Rank #1 (Strong Buy) value stocks list on April 25, 2024.
2024-04-25 05:40:21 - Zacks Investment Research
Best Income Stocks to Buy for April 25th
CIB, TAK and ASBFY made it to the Zacks Rank #1 (Strong Buy) income stocks list on April 25, 2024.
2024-03-25 13:07:32 - Seeking Alpha
2 More Potential Biotech Buyout Targets
M&A activity in the biotech/biopharma sector is expected to remain active due to significant cash on Big Pharma's balance sheets, key patent expirations, and declining revenue from Covid related products. The oncology space continues to be a hot and active area for deal volume, with global sales projected to reach $375 billion by 2027. Today, we profile two smaller oncology names that appear to be logical acquisitions for larger concerns that want to expand their oncology footprints.